Study design

prospective

Country

Switzerland

Object

We used data from two prospective clinical trials (ClinicalTrials.gov NCT02265159 and DRKS00007105) evaluating focal HIFU treatment (n=95) and identified men who underwent S-RALP for treatment failure of PCa between September 2015 and January 2019. Clinical trials and subgroup alyses were approved by the local ethic committees (IRB No. KEK-ZH-Nr.2013-0415 and 2014-423M-MA/2015-401M-MA, IRB No.KEK-StV-Nr. 06/08 and 2015-549N-MA). Regarding details of the study protocol see Mortezavi et al.4 and von Hardenberg et al.9 We included patients with any detected PCa (WHO2016/ISUP GG 2 or 3) in the extended follow-up biopsy4 6 to 12 months after focal HIFU who subsequently underwent S-RALP. No routine TURP or HoLEP was performed prior to HIFU therapy. To compare S-RALP with pRALP a randomly matched double-sized control-group of treatment-ive men who underwent pRALP between May 2015 and January 2018 at the same institutions were chosen; matching variables included WHO2016/ISUP GG, preoperative PSA value, age, body mass index (BMI), prostate size, clinical T-stage, as well as preoperative ICIQ and IIEF-5 scores.

Robots remarks

four-arm DaVinci Surgical System (Intuitive Surgical Inc., Sunnivale, CA).

Sample size

39

Topic classification

Intraoperative operation

Keypoint

Salvage robotic-assisted laparoscopic radical prostatectomy should be offered to patients with an early relapse after focal high-intensity focused ultrasound. The early oncological outcome is satisfactory and functiol outcome one year postoperatively is similar to primary robotic-assisted laparoscopic radical prostatectomy. However, Salvage robotic-assisted laparoscopic radical prostatectomy is associated with a higher rate of Clavien-Dindo III complications (mainly, placement of a draige), of which patients should be informed beforehand.

Year